神经外科医师大会关于WHO II级弥漫性胶质瘤神经病理学的系统综述与循证指南:更新
该指南更新针对成人疑似或病理证实的WHO II级弥漫性胶质瘤,就组织病理诊断、IDH突变、1p/19q缺失、MGMT启动子甲基化、Ki-67/MIB1及ATRX突变检测和术中光学组织学方法提出推荐。多数检测获不同等级推荐,但MGMT常规检测、ATRX检测及术中光学组织学准确性证据不足。
要点
- Level I推荐对代表性手术样本行组织病理学分析以诊断低级别弥漫性胶质瘤。
- Level II推荐IDH基因突变检测用于分类和预后,Level III推荐1p/19q缺失检测用于少突胶质细胞瘤。
- MGMT启动子甲基化常规检测、ATRX突变检测及术中光学组织学方法均证据不足,不推荐常规使用。
核心结论
- 对成人疑似或病理证实的WHO II级弥漫性胶质瘤,组织病理学分析为Level I推荐,IDH突变检测为Level II推荐,1p/19q缺失和Ki-67/MIB1检测为Level III推荐。
- MGMT启动子甲基化常规检测、ATRX突变检测及术中光学组织学方法因证据不足,未获推荐。
研究设计与样本
- 该指南由神经外科医师大会制定,基于系统综述与循证方法,针对成人(年龄≥18岁)疑似低级别弥漫性胶质瘤或病理证实的WHO II级弥漫性胶质瘤患者提出推荐。
主要发现
- IDH基因突变评估通过IDH1 R132H抗体和/或IDH1/2突变热点测序,对低级别弥漫性胶质瘤具有高度特异性,推荐作为分类和预后的附加检测(Level II)。
- 1p/19q杂合性缺失检测通过FISH、array-CGH或PCR,推荐作为少突胶质细胞瘤病例的附加检测用于预后和潜在治疗计划(Level III)。
- Ki67/MIB1免疫组化推荐作为预后评估的选项(Level III)。
- MGMT启动子甲基化检测作为低级别弥漫性胶质瘤常规检测证据不足,推荐患者参加 properly designed 临床试验以评估该标志物价值。
- ATRX突变检测用于预测生存或制定治疗建议证据不足;术中光学组织学方法相比传统技术提高诊断准确性的证据不足。
关键数值与推荐
- Level I:对代表性手术样本行组织病理学分析以提供低级别弥漫性胶质瘤诊断。
- Level III:冰冻切片和细胞病理学/涂片评估应同时用于辅助术中低级别弥漫性胶质瘤诊断评估;切除标本优于活检标本以减少采样误差。
- Level II:通过IDH1 R132H抗体和/或IDH1/2突变热点测序评估IDH基因突变,推荐作为分类和预后的附加检测。
- Level III:通过FISH、array-CGH或PCR检测1p/19q杂合性缺失,推荐作为少突胶质细胞瘤病例的附加检测用于预后和潜在治疗计划。
- Level III:Ki67/MIB1免疫组化推荐作为预后评估的选项;MGMT启动子甲基化常规检测证据不足,推荐参加临床试验。
临床怎么用
- 对成人疑似低级别弥漫性胶质瘤,应使用代表性手术样本行组织病理学分析以提供诊断(Level I)。
- 术中可同时使用冰冻切片和细胞病理学/涂片评估辅助诊断;切除标本优于活检标本以减少采样误差(Level III)。
- 对病理证实的WHO II级弥漫性胶质瘤,推荐行IDH基因突变检测用于分类和预后(Level II),少突胶质细胞瘤病例推荐行1p/19q缺失检测用于预后和潜在治疗计划(Level III)。
- Ki67/MIB1免疫组化可作为预后评估的选项(Level III);MGMT启动子甲基化常规检测证据不足,推荐患者参加临床试验。
- ATRX突变检测用于预测生存或制定治疗建议证据不足;术中光学组织学方法相比传统技术提高诊断准确性的证据不足。
局限性
- MGMT启动子甲基化检测作为低级别弥漫性胶质瘤常规检测的证据不足。
- ATRX突变检测用于预测生存或制定治疗建议的证据不足。
- 术中光学组织学方法相比传统技术提高诊断准确性的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma. QUESTION: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult? RECOMMENDATION: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis. A resection specimen is preferred over a biopsy specimen, to minimize the potential for sampling error issues. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for IDH1 mutation (R132H and/or others) warranted? If so, is there a preferred method? RECOMMENDATION: Level II IDH gene mutation assessment, via IDH1 R132H antibody and/or IDH1/2 mutation hotspot sequencing, is highly-specific for low-grade diffuse glioma, and is recommended as an additional test for classification and prognosis. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for 1p/19q loss warranted? If so, is there a preferred method? RECOMMENDATION: Level III 1p/19q loss-of-heterozygosity testing, by FISH, array-CGH or PCR, is recommended as an additional test in oligodendroglial cases for prognosis and potential treatment planning. TARGET POPULATION: Patients with histologically proven WHO grade II diffuse glioma. QUESTION: In adult patients (age > 18 years) with histologically-proven WHO grade II diffuse glioma, is methyl-guanine methyl-transferase (MGMT) promoter methylation testing warranted? If so, is there a preferred method? RECOMMENDATION: There is insufficient evidence to recommend MGMT promoter methylation testing as a routine for low-grade diffuse gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the value of this and related markers for this target population. TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma. QUESTION: In adult patients (age ≥ 18 years) with histologically proven WHO grade II diffuse glioma, is Ki-67/MIB1 immunohistochemistry warranted? If so, is there a preferred method to quantitate results? RECOMMENDATION: Level III Ki67/MIB1 immunohistochemistry is recommended as an option for prognostic assessment. NEW RECOMMENDATION: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. QUESTION: Is testing for ATRX mutations helpful for predicting survival and making treatment recommendations? RECOMMENDATION: There is insufficient evidence to recommend ATRX mutation testing as a means of predicting survival or making treatment recommendations. TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. QUESTION: Does the addition of intraoperative optical histologic methods provide accuracy beyond the use of conventional histologic methods in diagnosis and management? RECOMMENDATION: There is insufficient evidence at this time to suggest that intraoperative optical histologic methods offer increased diagnostic accuracy when compared to conventional techniques.
引用
- Mandelberg N, Hodges TR, Wang TJC, et al. Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update. J Neurooncol. 2025. PMID: 39747718. doi:10.1007/s11060-024-04898-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。